10 research outputs found
Properties of Near-Net Shape Metallic Components Made by the Directed Light Fabrication Process
Mechanical Engineerin
Abstracts from the 20th International Symposium on Signal Transduction at the Blood-Brain Barriers
https://deepblue.lib.umich.edu/bitstream/2027.42/138963/1/12987_2017_Article_71.pd
Recommended from our members
Modeling and analysis of novel laser weld joint designs using optical ray tracing.
Reflection of laser energy presents challenges in material processing that can lead to process inefficiency or process instability. Understanding the fundamentals of non-imaging optics and the reflective propagation of laser energy can allow process and weld joint designs to take advantage of these reflections to enhance process efficiency or mitigate detrimental effects. Optical ray tracing may be used within a 3D computer model to evaluate novel joint and fixture designs for laser welding that take advantage of the reflective propagation of laser energy. This modeling work extends that of previous studies by the author and provides comparison with experimental studies performed on highly reflective metals. Practical examples are discussed
Recommended from our members
Rapid fabrication of materials using directed light fabrication
Directed light fabrication (DLF) is a rapid fabrication process that fuses gas delivered metal powders within a focal zone of a laser beam to produce fully dense, near-net shape, 3-dimensional metal components from a computer generated solid model. Computer controls dictate the metal deposition pathways, and no preforms or molds are required to generate complex sample geometries. The focal zone of the laser beam is programmed to move along or across a part cross-section, and coupled with a multi-axis sample stage, produces the desired part. By maintaining a constant molten puddle within the focal zone, a continuous liquid/solid interface is possible while achieving constant cooling rates that can be varied between 10 to 10{sup 4} K s{sup -1} and solidification growth rates (that scale with the beam velocity) ranging up to 10{sup 2} m s{sup -1}. The DLF technique offers unique advantages over conventional thermomechanical processes in that many labor and equipment intensive steps can be avoided. Moreover, owing to the flexibility in power distributions of lasers, a variety of materials can be processed, ranging from aluminum alloys to rhenium, and including intermetallics such as Mo{sub 5}Si{sub 3}. As a result, the rapid fabrication of conventional and advanced materials are possible
Recommended from our members
Refractory metal welding using a 3.3 kW diode pumped Nd:YAG laser.
Recent developments in multi-kilowatt continuous wave lasers allow fiber optic delivery to high-purity controlled atmosphere chambers and challenge electron beam welding with improvements in cost, complexity, beam quality and flexibility. Questions remain with respect to the performance of these lasers for refractory alloy welding regarding damaging back reflections, laser-plume interactions, and sufficiency of beam intensity and coupled energy. System performance for the welding of various refractory metal alloys and comparisons to electron beam welds will be presented
COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction
Objective The initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days)
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial
Background:
Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor.
Methods:
The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population).
Findings:
Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI.
Interpretation:
In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk